Leukemia/Lymphoma
RSSArticles
-
Did You Know?
-
Paclitaxel Hypersensitivity: It's the Vehicle That Gets You There
-
New Hope for Immunologic Approaches to Metastatic Melanoma
-
Lowering the Threshold for Prophylactic Platelet Transfusion: Is the Risk of
-
Concomitant and Subsequent Chemotherapy Enhances Responses to Advanced Nasophary
-
Systemic Radiation Therapy Using Receptor Specific Radioligands: Experience with
-
Cancer Screening's Next Chapter: Mobile CT Scanning for Lung Cancer
-
Lessons in Supportive Care, IX: Do Medical Care Interventions Ever Save Money?
-
Strategy to Overcome Rituximab Resistance in Patients with Indolent Lymphoma
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles). -
Second-line Docetaxel Improves Survival and Symptom Control in Advanced Esophagogastric Cancer
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone.